Congenica is a digital health company offering a clinical decision support platform for accelerated genomic data interpretation. Congenica software enables genomic medicine by integrating genetic data into healthcare, empowering clinicians to provide life-changing answers that transform the lives of individuals, patients and their families.
Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica is headquartered in Cambridge, UK, with a global footprint across the US and China. The Congenica platform is validated by the pivotal Genomics England 100,000 Genomes Project and the company is the exclusive clinical interpretation partner to the NHS Genomic Medicine Service.
Genetic diseases are technically difficult to diagnose, and patients often spend years waiting for a diagnosis. Congenica converts genomic data into actionable information, expediting the process through more efficient and accurate analysis. This supports healthcare professionals in providing patients with robust diagnoses and precise, personalised care.
In the media
30th April 2019
What drives the stand out success of genomics biotech pioneer, Congenica?
21st October 2019
Nonacus Unveils ExomeCG Product
to a media release, the new product has been co-developed with digital health technology company, Congenica, which specialises in software solutions that enable
18th October 2019
-Congenica Ltd - Nonacus introduces ExomeCG product to simplify molecular and cytogenomics data generation and interpretation
next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product designed by Congenica to simplify the generation and interpretation of